Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4843308 | 0.95 | DGAT2 (0.40) | DGAT2MAPK14MAPK11PI4KAPI4KB | |
| SCHEMBL4844959 | 0.92 | CCNT1 (0.39) | DGAT2MAPK14MAPK11CCNT1LPAR2 | |
| SCHEMBL4837403 | 0.89 | MAPK14 (0.42) | MAPK14MAPK11LPAR2CTSA | |
| SCHEMBL4833047 | 0.88 | MAPK14 (0.41) | MAPK14MAPK11LPAR2CTSA | |
| SCHEMBL4842430 | 0.87 | MAPK14 (0.41) | MAPK14MAPK11CTSACNR1 | |
| SCHEMBL4841030 | 0.86 | MAPK14 (0.41) | MAPK14MAPK11LPAR2CTSA | |
| SCHEMBL4013149 | 0.86 | MAPK14 (0.40) | MAPK14MAPK11CTSACNR1 | |
| SCHEMBL4845132 | 0.85 | MAPK14 (0.41) | MAPK14MAPK11LPAR2CTSA | |
| SCHEMBL4017385 | 0.85 | MAPK14 (0.41) | MAPK14MAPK11LPAR2CTSA | |
| SCHEMBL4841418 | 0.84 | MAPK14 (0.41) | MAPK14MAPK11LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | claimed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | MAP3K1, MAPK1, MAP3K8 | DGAT2 4662/4885MAPK14 70/4885MAPK11 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.